Zastumotide

Drug Profile

Zastumotide

Alternative Names: Astuprotimut-R; D1/3 MAGE-3 fusion protein; D1/3 MAGE-3 fusion protein SB MAGE-3; D1/3 MAGE-3 His; D1/3 MAGE-3 His fusion protein; GSK 1572932A; GSK 2132231A; GSK 249553; GSK1203486A; MAGE-A3; MAGE-A3 antigen specific cancer immunotherapeutic; MAGE-A3 ASCI; NSC 719274; SB 249553; SB MAGE-3; SID 534984

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Developer GlaxoSmithKline; Ludwig Institute for Cancer Research
  • Class Cancer vaccines; Immunotherapies; Peptides; Recombinant fusion proteins
  • Mechanism of Action Immunostimulants; MAGEA-3-protein-modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Malignant melanoma
  • No development reported Multiple myeloma
  • Discontinued Bladder cancer; Non-small cell lung cancer

Most Recent Events

  • 05 Jan 2017 No development reported - Phase-I for Multiple myeloma in USA (IM)
  • 15 Dec 2016 Biomarkers information updated
  • 15 Apr 2016 Interim adverse events and efficacy data from a phase II trial in Malignant melanoma (Inoperable/Unresectable, Combination therapy) presented at the 107th Annual Meeting of the American Association for Cancer Research (AACR 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top